NOS1 and Parkinson disease: Thus, considering BPC 157/Parkinson’s disease/Alzheimer’s disease, BPC 157 therapy was effective in Parkinson’s disease models, and it counteracted parkinsonogenic neurotoxin MPTP-induced tremor, rigor, akinesia, and gastric lesions and counteracted mortality in mice, reserpine-induced akinesia, catalepsy, hypothermia, and catalepsy induced by neuroleptics or NOS-blocker L-NAME application [198,199,200].